Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T cells in SysTemic B celL mediated autoimmunE Disease
DRKS00032279Phase 2Recruiting
- Sponsor
- Friedrich-Alexander University Erlangen-Nuremberg
- Start
- Jul 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD19 CAR-T cells in systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM) and 1 more, sponsored by Friedrich-Alexander University Erlangen-Nuremberg. Started Jul 2023; status: recruiting.
02
Drugs
CD19 CAR-T cells
03
Conditions
systemic lupus erythematosus (SLE)dermatomyositis (DM)polymyositis (PM)systemic sclerosis (SSc)
Beyond the preview
Go deeper on DRKS00032279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00032279.